Ginkgo Bioworks (DNA) Competitors $12.42 -0.36 (-2.78%) Closing price 08/27/2025 03:59 PM EasternExtended Trading$12.73 +0.30 (+2.45%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, MENS, KYMR, SRRK, BHC, XENE, AMRX, HCM, RARE, and NAMSShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS HUTCHMED Ultragenyx Pharmaceutical NewAmsterdam Pharma Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Is TWST or DNA more profitable? Twist Bioscience has a net margin of -23.51% compared to Ginkgo Bioworks' net margin of -136.56%. Twist Bioscience's return on equity of -29.03% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Ginkgo Bioworks -136.56%-43.25%-22.29% Does the media prefer TWST or DNA? In the previous week, Twist Bioscience had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 8 mentions for Twist Bioscience and 6 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.07 beat Ginkgo Bioworks' score of 0.34 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TWST or DNA? Twist Bioscience currently has a consensus target price of $49.40, suggesting a potential upside of 81.68%. Ginkgo Bioworks has a consensus target price of $9.50, suggesting a potential downside of 23.54%. Given Twist Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, TWST or DNA? Twist Bioscience has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Which has stronger earnings & valuation, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M5.24-$208.73M-$1.45-18.75Ginkgo Bioworks$227.04M3.24-$547.03M-$5.86-2.12 Do insiders & institutionals hold more shares of TWST or DNA? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTwist Bioscience beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$756.57M$3.10B$5.76B$21.26BDividend YieldN/A2.26%3.95%3.53%P/E Ratio-2.1221.0830.8529.20Price / Sales3.24396.73471.2153.54Price / CashN/A44.4437.7623.64Price / Book1.208.0610.135.36Net Income-$547.03M-$54.08M$3.26B$996.59M7 Day Performance5.95%2.51%2.86%2.99%1 Month Performance-10.87%3.55%4.02%2.88%1 Year Performance75.00%18.40%43.37%12.54% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.0272 of 5 stars$12.43-2.8%$9.50-23.5%+64.8%$756.57M$227.04M-2.12640Analyst ForecastTWSTTwist Bioscience4.0357 of 5 stars$28.02-0.4%$49.40+76.3%-39.7%$1.69B$312.97M-19.32990Positive NewsMENSJyong BiotechN/A$41.22-7.9%N/AN/A$3.13BN/A0.0031KYMRKymera Therapeutics2.9412 of 5 stars$43.62+2.3%$59.11+35.5%-13.6%$3.12B$47.07M-12.57170News CoverageSRRKScholar Rock4.5684 of 5 stars$31.52+0.4%$45.14+43.2%+280.5%$3.03B$33.19M-10.83140Positive NewsBHCBausch Health Cos4.3414 of 5 stars$8.02-3.8%$9.00+12.2%+22.1%$2.97B$9.63B30.8520,700Analyst RevisionXENEXenon Pharmaceuticals2.2529 of 5 stars$37.82-1.1%$53.20+40.7%-5.0%$2.92B$9.43M-10.65210Positive NewsAMRXAMNEAL PHARMACEUTICALS3.2642 of 5 stars$9.26-2.0%$11.60+25.3%+10.4%$2.91B$2.79B926.938,100Positive NewsInsider TradeHCMHUTCHMED2.6478 of 5 stars$16.43-0.1%$28.00+70.4%-13.6%$2.87B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.6681 of 5 stars$29.70+0.0%$81.50+174.4%-47.8%$2.86B$560.23M-5.371,294NAMSNewAmsterdam Pharma3.6432 of 5 stars$25.40+1.3%$41.20+62.2%+45.9%$2.86B$45.56M-15.684Analyst ForecastInsider Trade Related Companies and Tools Related Companies Twist Bioscience Competitors Jyong Biotech Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Bausch Health Cos Competitors Xenon Pharmaceuticals Competitors AMNEAL PHARMACEUTICALS Competitors HUTCHMED Competitors Ultragenyx Pharmaceutical Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access